How to Pay for GLP-1 When Medicare Says No: 6 Real Paths in 2026

Medicare Part D doesn't cover Wegovy when it's prescribed solely for weight loss — that's a federal statutory exclusion from 2003. However, Part D can cover Wegovy when it's prescribed to reduce major cardiovascular events in adults with established cardiovascular disease who are overweight or obese, an indication the FDA approved in 2024. Separately, the Medicare GLP-1 Bridge demonstration covers Wegovy at $50/month for eligible Part D beneficiaries from July 1, 2026 through December 31, 2027.

The Medicare Modernization Act of 2003 prohibits Part D from covering medications used solely for weight loss. Ozempic is FDA-approved for Type 2 diabetes — not weight loss — so Medicare Part D plans cover it for diabetes but not when it's prescribed off-label for weight management. Ozempic is not included in the Medicare GLP-1 Bridge; the Bridge covers only Wegovy, the Zepbound KwikPen, and Foundayo.

Yes. Medicare provides five appeal levels for any Part D coverage denial, starting with a coverage determination or formulary exception request to your plan. A Letter of Medical Necessity from your prescriber that ties the prescription to a covered FDA-approved indication and to your plan's specific clinical criteria is the most important factor. Many denials are procedural and can be fixed when complete documentation is filed — but appeals will not generally overturn the federal weight-loss exclusion or Bridge eligibility criteria.

Wegovy's retail list price is around $1,349/month. The cheapest legitimate self-pay path is NovoCare Pharmacy: $199/month for the first two fills at the lowest injection doses (intro pricing), then $349/month ongoing. The Wegovy pill (FDA-approved December 2025) starts at $149/month for the lowest dose with limited-time intro pricing. The Wegovy 12-month subscription through partner telehealth providers locks in $249/month for the injection.

The Medicare GLP-1 Bridge is a CMS demonstration program that pays for Wegovy, the Zepbound KwikPen, and Foundayo at a flat $50/month for eligible Medicare Part D beneficiaries. It launches July 1, 2026 and was extended through December 31, 2027 after CMS announced on April 21, 2026 that the broader BALANCE Model would not roll out in Medicare Part D as planned. The Bridge operates outside the regular Part D benefit, uses Humana as the central processor, and uses dedicated codes (BIN 028918, PCN MEDDGLP1BR) for pharmacy claims.

No. Federal anti-kickback law excludes anyone enrolled in Medicare, Medicaid, or Tricare from using manufacturer copay/savings cards. The "$25/month" advertising for the Wegovy Savings Card and Zepbound Savings Card does not apply to Medicare beneficiaries.

Probably not for free, but you can usually get one significantly cheaper. Manufacturer Patient Assistance Programs do not currently list Wegovy, Zepbound, Mounjaro, or Foundayo for Medicare beneficiaries — that's worth knowing because some older guides still suggest otherwise. The realistic low-income path is Extra Help (Low-Income Subsidy), which can cap your copay on covered Part D drugs at up to $5.10 (generic) / $12.65 (brand) in 2026, plus the Medicare Prescription Payment Plan to spread costs across the year, plus your state's SPAP if one exists.

The Bridge currently runs through December 31, 2027. CMS originally planned for the Bridge to run only July–December 2026 and then bridge into the BALANCE Model in Medicare Part D in January 2027. On April 21, 2026, CMS announced that BALANCE would not launch in Medicare Part D as planned, and the Bridge was extended through 2027. The status of any successor program after 2027 has not been finalized.

You still qualify based on your starting BMI. CMS clarified that Bridge eligibility is judged at the time GLP-1 therapy was initiated, not at the time of the prior-authorization request. If you started at a BMI of 37 and have dropped to 30 since, your prescriber attests you met the original BMI ≥35 criterion at the time therapy began.

Ask whether the request was submitted under Wegovy's FDA-approved cardiovascular risk-reduction indication through regular Part D — not as a weight-loss prescription. The FDA approved Wegovy in 2024 to reduce cardiovascular death, heart attack, and stroke risk in adults with established CV disease who are overweight or obese. This is a Part D-covered indication today, before the Bridge launches.

Ask whether your chart supports Zepbound's FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity, which the FDA approved in December 2024. If it does, your prescriber can resubmit through regular Part D under the OSA indication.

The Medicare Prescription Payment Plan (MPPP) is a 2025+ Medicare benefit that lets you spread your covered Part D drug costs across the year in monthly payments. It does not lower your total cost — your annual Part D out-of-pocket is still capped at $2,100 in 2026 — but it stops you from paying $400+ in any single month. It applies only to drugs covered under regular Part D, not the Bridge.

Sometimes — but with limits. Ro's own page states it cannot coordinate GLP-1 medication coverage for government insurance plans like Medicare, Medicaid, or TRICARE. So telehealth is the right fit when you've decided on a cash-pay path, not when you need help with a Part D coverage appeal. For Part D coverage and appeals, work with your prescriber, your plan, or a free SHIP counselor.

No. Compounded products are not FDA-approved and are not interchangeable with FDA-approved branded medications. With NovoCare Wegovy now at $199–$349/month, the price gap that used to make compounded look attractive has shrunk. For most older adults with comorbidities, an FDA-approved option with regulated supply and clinical oversight is what we'd prioritize first.

Maybe, but don't switch based on one medication without help. Plan formularies, prior authorization rules, and specialty tier placement vary widely. Use SHIP/Medicare counseling to compare your full medication list and overall plan benefits during open enrollment (October 15 – December 7, 2026 for 2027 coverage). Switching wrong can cost more on your other medications than it saves on a GLP-1.